ELEPHANTIASIS NOSTRAS VERRUCOSA

ELEPHANTIASIS NOSTRAS VERRUCOSA was reported 8 times

ELEPHANTIASIS NOSTRAS VERRUCOSA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Autologous Cellular Immunotherapy [EPC] 1 0.0002
1 Kinase Inhibitor [EPC] 6 0.0000
2 Janus Kinase Inhibitor [EPC] 1 0.0000
3 Thiazide Diuretic [EPC] 1 0.0000
4 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
5 Corticosteroid [EPC] 3 0.0000
6 Folate Analog Metabolic Inhibitor [EPC] 1 0.0000
7 Thalidomide Analog [EPC] 1 0.0000